RxDoctor Payments Data

Issam Al-Bitar, MD

Interventional Cardiology · Pensacola, FLNPI 1083608087

Payments from drug & device makers

$1,285in general payments, 2019–2025

Across 36 payments — averaging $35.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$429
  • Medtronic$209
  • Novartis$197
  • Boston Scientific$125
  • Kestra Medical Technology Services, Inc.$97
  • E.r. Squibb & Sons, L.L.C.$66
  • plus $162 from 8 others

What the payments were for

  • Food & beverage$1,285100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,285 in reported general payments places this provider in the 10th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$97,972
Medicare patients
956
Services billed
2,630

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban310$355,463
XareltoRivaroxaban58$75,676
Repatha SureclickEvolocumab13$7,116
Praluent PenAlirocumab13$6,586
Diltiazem 24hr Er (Cd)Diltiazem Hcl190$5,593
Metoprolol Succinate327$3,830
Rosuvastatin Calcium307$3,610
Flecainide Acetate86$3,158
Ranolazine ErRanolazine23$2,477
Carvedilol219$2,029
Ezetimibe139$1,867
Furosemide330$1,842
Atorvastatin Calcium260$1,733
Losartan Potassium225$1,584
Metoprolol Tartrate206$1,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$355,463310 claims
Johnson & JohnsonXarelto$13$75,67658 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Pensacola

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →